Managing therapeutic resistance in breast cancer: from the lncRNAs perspective.

摘要: Breast cancer (BC) is the most common female malignancy and second leading cause of cancer-related death worldwide. In spite significant advances in clinical management, mortality BC continues to increase due frequent occurrence treatment resistance. Intensive studies have been conducted elucidate molecular mechanisms underlying therapeutic resistance, including increased drug efflux, altered targets, activated bypass signaling pathways, maintenance stemness, deregulated immune response. Emerging evidence suggests that long noncoding RNAs (lncRNAs) are intimately involved therapy resistance through multiple modes action. Therefore, an in-depth understanding implication lncRNAs therapies may improve outcome patients. Here, we highlight role regulating with emphasis on lncRNAs-mediated different scenarios, discuss potential as novel biomarkers or targets